Merck & Co., Inc. (NYSE:MRK) is one of the 15 Best Stocks to Invest in for Financial Stability. FDA Grants Breakthrough Therapy Designation to Merck & Co., Inc. (MRK)’s Raludotatug Deruxtecan for Platinum-Resistant Ovarian On September 15, 2025, Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo revealed that the FDA granted Breakthrough Therapy Designation to raludotatug deruxtecan for platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers expressing CDH6 after bevacizumab treatment. Th ...